The position of strontium ranelate in today’s management of osteoporosis

Osteoporosis International

Volumn 26, Issue 6, 2015, Pages 1667-1671

  Reginster, J Y ^a   Brandi, M L ^b   Cannata Andia J ^c   Cooper, C ^d   Cortet, B ^e   Feron, J M ^f   Genant, H ^g   Palacios, S ^h   Ringe, J D ⁱ   Rizzoli, R ^j  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF FLORENCE   (Italy)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Instituto Palacios de Salud Y Medicina de la Mujer   (Spain)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

^j GENEVA UNIVERSITY HOSPITALS   (Switzerland)

more..

Author keywords

Efficacy; Osteoporosis; Safety; Strontium ranelate; Treatment

Indexed keywords

STRONTIUM RANELATE; BONE DENSITY CONSERVATION AGENT; THIOPHENE DERIVATIVE;

CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FRAGILITY FRACTURE; HEALTH CARE COST; HEART MUSCLE ISCHEMIA; HUMAN; MEDICAL HISTORY; OSTEOPOROSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; DRUG APPROVAL; RISK ASSESSMENT; STANDARDS; TREATMENT OUTCOME;

BONE DENSITY CONSERVATION AGENTS; DRUG APPROVAL; DRUG PRESCRIPTIONS; HUMANS; OSTEOPOROSIS; RISK ASSESSMENT; THIOPHENES; TREATMENT OUTCOME;

EID: 84931287796     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3109-y     Document Type: Review

References (21)

1. Kanis JA, Borgstrom F, Compston J et al (2013) SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos 8:144
2. Hiligsmann M, Bruyere O, Reginster JY (2010) Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Bone 46:440–446
3. Hiligsmann M, Bruyere O, Reginster JY (2010) Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos Int 21:157–165
4. Hiligsmann M, Evers SM, Ben SW et al (2015) A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. Pharmacoeconomics 33:205–224
5. European Medicines Agency (2014) Strontium ranelate. Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000560/WC500045525.pdf. Accessed 18 July 2014
6. Reginster JY (2014) Cardiac concerns associated with strontium ranelate. Expert Opin Drug Saf 13:1209–1213
7. Compston J (2014) Strontium ranelate lives to fight another day. Maturitas 78:75–76
8. European Medicines Agency (2013) Assessment report—periodic safety update report (EPAR - Protelos-H-C-560-PSU31). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000560/WC500147168.pdf. Accessed 3 Feb 2014
9. Audran M, Jakob FJ, Palacios S et al (2013) A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years. Rheumatol Int 33:2231–2239
10. Cooper C, Fox KM, Borer JS (2014) Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case–control study in the CPRD. Osteoporos Int 25:737–745
11. Abrahamsen B, Grove EL, Vestergaard P (2014) Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporos Int 25:757–762
12. Svanström H, Pasternak B, Hviid A (2014) Use of strontium ranelate and risk of acute coronary syndrome: cohort study. Ann Rheum Dis 73:1037–1043
13. Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468
14. Reginster JY, Seeman E, De Vernejoul MC et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816–2822
15. Kanis JA, Johansson H, Odén A et al. (2014) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis: the impact of severe osteoporosis and contraindications. Abstract OC25. Presented at the World Congress on Osteoporosis and Osteoarthritis and Musculoskeletal Diseases. WCO-IOF-ESCEO, Seville, Spain
16. Falaschetti E, Mindell J, Knott C et al (2014) Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet 383:1912–1919
17. Aspray TJ, Francis RM (2012) Treatment of osteoporosis in women intolerant of oral bisphosphonates. Maturitas 71:76–78
18. Cramer JA, Silverman S (2006) Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 119:S12–S17
19. Rabenda V, Mertens R, Fabri V et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811–818
20. Tadrous M, Wong L, Mamdani MM et al (2014) Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos Int 25:1225–1235
21. Kanis JA, Cooper C, Hiligsmann M et al (2011) Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int 22:2565–2573